Novel oral agents currently used in DM management (i.e., sodium-glucose cotransporter 2 (SGLT2) inhibitors, glucagon-like peptide 1 receptor agonists (GLP1-RAs)) enable a reduction in hospitalization rates for HF in DM patients independently of the presence of HF at baseline (84, 85). This evidence concerns the gene SLC5A2 and diabetes mellitus.